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Abstract. Cisplatin is a commonly used drug for cancer
treatment by crosslinking DNA, leading to apoptosis of
cancer cells, resistance to cisplatin treatment often occurs,
leading to relapse. Therefore, there is a need for the development of more effective treatment strategies that can
overcome chemoresistance. Myricetin is a flavonoid from
fruits and vegetables, showing anticancer activity in various
cancer cells. In this study, we found myricetin exhibited
greater cytotoxicity than cisplatin in two cisplatin-resistant
ovarian cancer cell lines, OVCAR-3 and A2780/CP70, and it
was less cytotoxic to the normal ovarian cell line IOSE-364.
Myricetin selectively induced apoptosis in both cisplatinresistant cancer cell lines, but did not induce apoptosis in
the normal ovarian cell line. It induced both Bcl-2 familydependent intrinsic and DR5 dependent extrinsic apoptosis
in OVCAR-3 cells. P53, a multifunctional tumor suppressor,
regulated apoptosis in OVCAR-3 cells through a Bcl-2
family protein-dependent pathway. Myricetin did not induce
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cell cycle arrest in either ovarian cancer cell line. Because of
its potency and selectivity against cisplatin-resistant cancer
cells, myricetin could potentially be used to overcome cancer
chemoresistance against platinum-based therapy.
Introduction
The human health and life are under constant serious threat
of cancer. Surgery, radiation, and chemotherapy have been
the most commonly utilized methods for therapy of ovarian
cancer. Recently, chemotherapy has become the predominant
mode of treatment. Platinum drugs, such as cisplatin and its
analogues, are the most frequently used agents for the treatment of human cancer. Initially, cisplatin responsiveness is
high, however, a large number of cancer patients will relapse
with cisplatin-resistant disease due to many mechanisms
including increased detoxification of the drug, changes in
cellular efflux and uptake of the drug, increased DNA repair
and inhibition of apoptosis (1). Moreover, it causes unacceptable rates of normal cell toxicity and a number of side-effects,
such as nephrotoxicity, neurotoxicity, ototoxicity electrolyte
disturbance, myelotoxicity, hemolytic anemia, nausea and
vomiting (2-5). Therefore, novel therapies and more selective
drugs are needed for the treatment of human cancer (6).
The cell cycle is the series of events that take place in a
cell leading to its division and duplication, resulting in two
daughter cells. It can be divided into three periods: interphase
(G1, S and G2 phases), the mitotic phase (M phase) and cytokinesis. A dysregulation of cell cycle components may lead
to tumor formation (7), and investigational anticancer drugs
have recently focused on the molecular targets involved in
cell cycle control mechanisms (8,9).
Apoptosis is a process of programmed cell death (PCD)
that occurs in multicellular organisms. Excessive apoptosis
causes atrophy, whereas defective apoptotic processes result
in uncontrolled cell proliferation, implicated in a wide
variety of diseases such as cancer. It has been reported that
a decreased susceptibility of cancer cells to apoptosis was
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tightly associated with drug resistance. Therefore, inducing
apoptosis in cancer cells may be a promising strategy to
overcome resistance (6). Many mechanisms are connected to
the failure to develop apoptosis in cancer cells, including the
expression of P-glycoprotein and p53 mutations. Two major
pathways leading to apoptosis, the intrinsic (mitochondrial)
and extrinsic (receptor-mediated) pathways, have been
delineated. The Bcl-2 protein family regulates the intrinsic
apoptotic pathway by controlling the permeability of the
mitochondrial membrane and the release of the pro-apoptotic
factors (10). Tumor necrosis factor-related apoptosis-inducing
ligand (TRAIL), including Apo2L/TRAIL, regulates the
extrinsic apoptotic pathway by engaging its receptor.
Flavonoids are natural polyphenols present in a variety
of foods, especially fruits and vegetables. The anticancer
activity of flavonoids isolated from plants have been widely
studied. It has been reported that flavonoids display anticancer
characteristics and might be able to prevent oxidation and
inflammation, diminish angiogenesis and cell proliferation,
and induce apoptosis (11). Myricetin (Fig. 1A) is a member of
the flavonoid class of phenolic compounds with antioxidant
properties (12). It can be found in fruits, vegetables, nuts,
berries, tea and red wine (13,14). Previous studies have
reported myricetin induces apoptosis in various cancer cells,
such as in hepatoma, pancreatic cancer, esophageal cancer
and colon carcinoma cells (15-18).
In this study, we examined the effects of myricetin apoptosis induction and cell cycle arrest in two platinum-resistant
ovarian cancer cell lines: A2780/CP70 and OVCAR-3. The
mechanisms involved in the effects of myricetin were also
investigated.
Materials and methods
Cell culture and reagents. Human ovarian cancer cell
lines, OVCAR-3 and A2780/CP70, were kindly provided by
Dr B. Jiang, Department of Microbiology, Immunology, and
Cell Biology, West Virginia University, Morgantown, WV,
USA. IOSE-364, normal ovarian surface epithelial cells from
healthy women, but immortalized with SV40 T/t, were a gift
from Dr N. Auersperg at the University of British Columbia,
Canada (19). All cell lines were maintained in RPMI-1640
medium (Sigma, St. Louis, MO, USA) supplemented with
10% US-qualified fetal bovine serum (Invitrogen, Grand
Island, NY, USA). All cells were maintained in a humidified
incubator with 5% CO2 at 37˚C. Myricetin was purchased
from J&K Chemical Technology (Beijing, China). It was
dissolved in dimethyl sulfoxide (DMSO) to make stock
solutions of 100 mM, and equal amounts of DMSO were
included in controls for every experiment. The primary
antibodies against caspase-3, -7, -8, and -9, Bax, Bcl-2, DR5,
Puma, FADD, and p21 were purchased from Cell Signaling
Technology, Inc. (Danvers, MA, USA). The primary antibodies against p53, cmyc, Bcl-xl and GAPDH were purchased
from Santa Cruz Biotechnology Inc. (Santa Cruz, CA, USA).
Cell viability. Cell growth inhibition was determined by
measuring 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) dye absorbance. The cells (1x104) were
seeded into 96-well, incubated at 37˚C. Cells were incubated
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overnight for attaching to the bottom and then treated with
different concentrations of myricetin (5-80 µM) or DMSO
(as vehicle). After 24 h, the medium was removed, and 100 µl
MTT (1 mg/ml) were added to each well and then incubated
at 37˚C for 4 h in the dark. After removing the supernatant,
the formed formazan crystals were dissolved in 200 µl
DMSO, and absorbance was measured at 570 nm.
Chicken chorioallantoic membrane assay. Specific pathogenfree fertile chicken eggs (Charles River Laboratories, North
Franklin, CT, USA) were slowly turned by an automatic egg
turner (G.Q.F. Manufacturing Co., Savannah, GA, USA) and
incubated at 37.5˚C. The cells (1.2x10 6) were suspended in
20 µl FBS-free medium, mixed with 80 µl of Matrigel (BD
Bioscience) and 0- or 20-µM myricetin, incubated on an autoclaved silicone mat for 30 min for gelation, and implanted
into the chorioallantoic membrane (CAM) of a 9-day-old
chicken embryo. After incubating another 5 days, the tumor
implants were measured for tumor weight.
Flow cytometry analysis of cell apoptosis. The apoptosis
effects of myricetin on ovarian cells were determined by
Alexa Fluor 488 Annexin V/Dead Cell Apoptosis kit from
Invitrogen. A2780/CP70, OVCAR-3 and IOSE-364 cells
(10 6/dish) treated with myricetin or DMSO for 24 h were
washed with cold PBS twice and re-suspended in binding
buffer. An aliquot of 100 µl of the cell solution (1x105 cells)
was transferred to a 5-ml tissue culture tube. Subsequently,
5 µl of FITC Annexin V and 1 µl propidium iodide (PI)
were added to the cells. The cells were gently vortexed and
incubated for 15 min at room temperature in the dark. The
next step involved the addition of 400 µl of 1X binding buffer
to each tube. The samples were analyzed by flow cytometry
(FACSCalibur system, BD Biosciences, San Jose, CA, USA).
Apoptosis assessment by Hoechst 33342 staining. OVCAR-3
cells (106/dish) treated with various concentrations of myricetin and pifithrin- α (PFT- α) (Sigma) for 24 h were washed
with cold PBS and stained with 10 µg/ml Hoechst 33342
(Sigma) in PBS for 10 min in the dark at 37˚C. Cell apoptosis
was examined under a fluorescence microscope (Zeiss).
Flow cytometry analysis of the cell cycle. Cells treated
with various concentrations of myricetin for 24 h were
digested by trypsin, collected by 1,000 rpm centrifugation for 10 min, and then washed with cold PBS. The cell
pellets were suspended with 70% ethanol, stored at -20˚C.
After centrifugation at 1,000 rpm for 6 min, the cell pellets
were re-suspended in PBS, collected by centrifugation, and
incubated with 180 µg/ml RNase A at 37˚C for 15 min. Flow
cytometry (FACSCalibur system, BD Biosciences) was used
for detection after 50 µg/ml propidium iodide (final concentration) was added to cell pellets for 15-min staining. Data
were plotted and analyzed by using FCS software (De Novo
Software, Los Angeles, CA, USA).
Caspase-3/7 and caspase-9 assay. A2780/CP70 and
OVCAR-3 cells were seeded into 96-well plates (1x104/well)
and incubated overnight at 37˚C. Cells were treated with
different concentrations of myricetin (5-20 µM) or DMSO
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Figure 1. Myricetin inhibits cell viability in ovarian cancer cells. (A) Structure of myricetin. (B) Cells (1x104/well) were seeded in 96-well plates, incubated overnight, and then treated with myricetin for 24 h. Cell viability was determined by an MTT-based method and expressed as percentages of control.
(C) Myricetin suppressed OVCAR-3 cells growth in vivo. Chicken chorioallantoic membrane (CAM) assay shows tumor without myricetin treatment, and
treated with 20 µM myricetin. After 5 days of treatment, the tumors were excised. Weight of xenografted tumor implanted on CAM treated with and without
myricetin (0 and 20 µM). *p<0.05 as compared to control.

for 4 h. After treatment, Caspase-Glo 3/7 or Caspase-Glo 9
Assay kit (Promega) was used to detect the caspase-3/7 or
caspase-9 enzymatic activities in both ovarian cancer cell
lines. Enzymatic activities were normalized by total protein
levels and were expressed as a percentage of the untreated
control.

siRNA or control siRNA (Santa Cruz) using jetPRIME™
DNA and siRNA transfection reagent (VWR International,
Radnor, PA, USA) according to the manufacturer's protocol.
After 24 h, cells were treated with myricetin or DMSO. Cell
lysates were collected for western blotting to test Bad, Bax,
Bcl-xl, cmyc, p53 and p21 proteins.

Western blotting. Ovarian cancer cells were seeded in 60-mm
dishes at the concentration of 106/dish, incubated overnight,
and then treated with various concentrations of myricetin
for 24 h. The cells were lysed in 100 µl mammalian protein
extraction reagent including 1 µl Halt protease, 1 µl phosphatase inhibitor, and 2 µl EDTA (M-PER, Pierce, Rockford,
IL, USA). Total protein levels were determined by a BCA
Protein Assay kit (Pierce). The cell lysates were separated by
SDS-PAGE and blotted onto a nitrocellulose membrane with
a Mini-Protean 3 system (Bio-Rad, Hercules, CA, USA).
The membranes were blocked in 5% non-fat milk (dissolved
in Tris-buffer saline containing 0.1% Tween-20) for 1 h at
room temperature. The membranes were incubated with
the primary antibodies and secondary antibody dilutions,
washed with TBST. The antigen-antibody complex was visualized with the SuperSignal West Dura Extended Duration
Substrate (Pierce).

Statistical analysis. The experiments were performed at
least three times. Results were expressed as mean ± standard
error of mean (SEM) using Microsoft Excel (2007). SPSS
(Version 18.0 for Windows) was used to perform statistical
assessment. The results were analyzed using post hoc test
(2-sided Dunnett's test) and one-way analysis of variance
(ANOVA) to test differences between each treatment and
control. A p-value of <0.05 was considered statistically
significant.

Transfection with small interfering RNA (siRNA). OVCAR-3
cells were seeded in 60-mm dishes at 5x105/dish and incubated overnight before transfection with p53 siRNA, p21

Results
Effect of myricetin on ovarian cancer cell proliferation.
MTT assay was performed after treatment of ovarian cancer
and normal ovarian cells with myricetin to investigate the
effect of myricetin on the viability of platinum-resistant
ovarian cancer cells. We observed that compared with
controls (myricetin 0 µM), myricetin significantly reduced
the viability of A2780/CP70 and OVCAR-3. Cell viability
with myricetin treatment (5-80 µM) for 24 h ranged from
93.8 to 17.4% (p<0.05) for A2780/CP70 cells (Fig. 1B).
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Figure 2. Myricetin induced apoptosis in ovarian cancer cells A2780/CP70 and OVCAR-3 but not the normal ovarian cells IOSE-364. (A) Cells treated with
myricetin for 24 h, were collected, stained with PI and Annexin V, analyzed by flow cytometry to measure the apoptotic rate. (B) Cells were treated with
myricetin for 4 h, and caspase-3/7 enzymatic activity was determined using Caspase-Glo 3/7 assay kit. *p<0.05 as compared to control.

Figure 3. Myricetin did not induce cell cycle arrest in ovarian cancer cells A2780/CP70 and OVCAR-3. Cells treated with myricetin for 24 h, were collected,
stained with PI, analyzed by flow cytometry to measure cell phase division.

Similarly, myricetin also reduced viability of OVCAR-3
cells at concentrations of 10 µM myricetin and above. Cell
viability was significantly decreased from 71.5% at a concentration of 10 µM myricetin to 12.5% at a concentration of
80 µM myricetin (p<0.05) (Fig. 1B). We also examined the
growth-inhibitory activity of myricetin on IOSE-364 normal
ovarian cells (Fig. 1B). Myricetin had higher level of cytotoxicity in ovarian cancer cells A2780/CP70 and OVCAR-3
than on normal ovarian cells IOSE-364, indicating that
cisplatin-resistant ovarian cancer cells were more sensitive
to myricetin than normal ovarian cells. In CAM models,
myricetin reduced typical tumor growth of OVCAR-3 cells.
The tumors treated with 20 µM myricetin were smaller and
lighter than corresponding controls (Fig. 1C).
Myricetin induces apoptosis in A2780/CP70 and OVCAR-3
cells. For the purpose of investigating whether myricetin
inhibited cell growth by inducing apoptosis, the apoptosis
rates of ovarian cancer cell lines A2780/CP70, OVCAR-3,
and normal ovarian cells IOSE-364 were treated with myricetin (5-30 µM) for 24 h, and analyzed by flow cytometry after

Annexin V and propidium iodide (PI) staining. As shown in
Fig. 2A, myricetin significantly induced apoptosis in the two
ovarian cancer cells, especially in OVCAR-3, but it did not
induce apoptosis in the normal ovarian cells IOSE-364. For
A2780/CP70 and OVCAR-3, the apoptosis rates were 3.0 and
3.8% when not treated with myricetin, which was increased
to the maximum apoptosis rates of 42.1 and 84.2% at the
concentration of 30 µM myricetin. However, the treatment of
myricetin did not increase the IOSE-364 cell apoptosis rate
(Fig. 2A). Caspase-Glo 3/7 Assay kit was used to confirm
that myricetin induces apoptosis in ovarian cancer cells.
As shown in Fig. 2B, compared to controls, the caspase-3/7
enzymatic activities were maximally increased to 1.68- and
2.20-fold in A2780/CP70 and OVCAR-3 when treated with
20 µM myricetin for 4 h. These results indicate that myricetin
inhibited cell growth of ovarian cancer cells at least partly
through the induction of apoptosis.
Myricetin does not induce cell cycle arrest in A2780/CP70
and OVCAR-3 cells. To investigate whether the growthinhibitory effect of myricetin on ovarian cancer cells was
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Figure 4. Myricetin activated the intrinsic and extrinsic apoptotic pathway. (A) Myricetin decreased the levels of procaspase-9, Bcl-2 and Bcl-xl and increased
levels of Bad and Bax in A2780/CP70 and OVCAR-3 ovarian cancer cells. However, myricetin had no effect on the expression of Puma protein. (B) Cells
were treated with myricetin 4 h, and determined caspase-9 enzymatic activities using Caspase-Glo 9 Assay kit. *p<0.05 as compared to control. (C) Myricetin
decreased the levels of procaspase-8 and increased levels of DR5 (p40) in OVCAR-3 but not A2780/CP70 cells. However, myricetin had no effect on the
expression of FADD in either of the ovarian cancer cells.

caused by cell cycle arrest, cell cycle phase distribution of
cells treated with myricetin (5-20 µM) for 24 h was analyzed
by flow cytometry after PI staining. As shown in Fig. 3,
myricetin had little effect on inducing cell cycle arrest in
A2780/CP70 and OVCAR-3 cells. These results indicate that
myricetin inhibited ovarian cancer cell growth through a
mechanism separate from cell cycle arrest.
Effect of myricetin on the intrinsic and extrinsic apoptotic
pathway. The intrinsic apoptotic pathway and extrinsic
apoptotic pathway are the two main pathways which induce
apoptosis in cancer cells. An investigation was conducted to
determine whether myricetin induces apoptosis through the
intrinsic pathway in ovarian cancer cell lines A2780/CP70
and OVCAR-3. The expression of Puma, Bcl-2, Bcl-xl, Bax,
Bad and caspase-9 proteins were detected by western blotting. As shown in Fig. 4A, the expression of Bax and Bad
proteins was increased, while the Bcl-2 and Bcl-xl protein
levels were decreased when treated with myricetin. However,
the procaspase-9 and Puma protein levels were not changed
by treatment with myricetin. The cleaved caspase-9 protein
was not detected, suggesting that it may be degraded after
activation from procaspase-9. Caspase-Glo 9 Assay kit
was used to detect changes in caspase-9 enzymatic activities when treated with myricetin. The test was found to be
consistent with the western blotting result, which shows that
myricetin had no effect on the caspase-9 enzymatic activities
of A2780/CP70 and OVCAR-3 cells (Fig. 4B). These results
indicate that myricetin might induce the intrinsic pathway
in A2780/CP70 and OVCAR-3 cells through Bcl-2 family
proteins.
Next, the role of the extrinsic pathway in myricetininduced apoptosis was determined. Myricetin increased

the expression of matured DR5 and decreased the levels of
procaspase-8 in OVCAR-3 cells but not A2780/CP70 cells
(Fig. 4C). FADD protein levels were not changed in both
ovarian cancer cell lines treated with myricetin. Myricetin
might induce the extrinsic pathway in OVCAR-3 cells
through a DR5 and caspase-8 dependent pathway. However,
the induction of apoptosis in A2780/CP70 cells might be
through an extrinsic-independent pathway.
Role of p53 in the myricetin-induced apoptosis in OVCAR-3
cells. P53, a tumor suppressor protein, is involved in several
cellular outcomes such as apoptosis and angiogenesis (20).
Therefore, we examined some proteins which are associated with p53 to clarify whether myricetin inhibits viability
in A2780/CP70 and OVCAR-3 cells via the p53 protein
(Fig. 5A). We found that myricetin upregulated expression
of the p53 and p21 proteins and downregulated expression of
the oncogene cmyc protein.
The inhibitor of pifithrin- α (PFT- α) was used to investigate the role of p53 on myricetin-induced apoptosis in
OVCAR-3 cells. Treatment with 20 µM pifithrin- α significantly reduced the apoptotic rates and caspase-3/7 enzymatic
activities in OVCAR-3 cells induced by myricetin (Fig. 5B
and C). Fig. 5D shows knockdown of p53 by specific siRNA
(50 nM) resulted in abrogation of myricetin-increased levels
of Bax, Bad, and p21 proteins and myricetin-decreased
levels of cmyc and Bcl-xl proteins. These results indicate
that p53-associated intrinsic pathways were, at least partly,
involved in myricetin-induced apoptosis in ovarian cancer
cells.
Role of p21 in the myricetin-induced apoptosis in OVCAR-3
cells. The p21 siRNA was used to investigate the role of

Huang et al: Myricetin inhibits cisplatin-resistant cancer cells

1499

Figure 5. Myricetin induces apoptosis on ovarian cancer cells in a p53-dependent pathway. (A) Myricetin decreased the expression of protein cmyc, and
increased levels of protein p21 and p53. (B) Cells were treated with myricetin and p53 inhibitor pifithrin- α (PFT-α) for 24 h, stained with Hoechst 33342,
apoptotic rate measured by fluorescence microscope. *p<0.05 as compared to myricetin-treated control. (C) Cells were treated with myricetin and PFT-α for
4 h, and caspase-3/7 enzymatic activity was determined using Caspase-Glo 3/7 assay kit. *p<0.05 as compared to myricetin-treated control. (D) Knockdown
p53 resulted in abrogation of myricetin-increased levels of Bad, Bax, p21 and p53 and decreased levels of cmyc, Bcl-2 and Bcl-xl in OVCAR-3 cells. Cells were
seeded in 60-mm dishes, incubated overnight, and then transfected with p53 siRNA or control siRNA. After 24 h, cells were treated with myricetin or DMSO.
Cell lysates were collected for western blotting.

Figure 6. Myricetin induces apoptosis on ovarian cancer cells in a p21-independent pathway. (A) Knockdown p21 had no effect on the myricetin-induced
apoptosis in OVCAR -3 cells. Cells were seeded in 60-mm dishes, incubated overnight, and then transfected with p21 siRNA or control siRNA. After 24 h,
cells were treated with myricetin or DMSO for another 24 h, stained with Hoechst 33342, apoptotic rate was measured by fluorescence microscope. *p<0.05
as compared to myricetin-treated control. (B) Cells were transfected with p21 siRNA or control siRNA for 24 h, treated with myricetin or DMSO for another
24 h, caspase-3/7 enzymatic activity was determined using Caspase-Glo 3/7 assay kit. *p<0.05 as compared to myricetin-treated control.

p21 on myricetin-induced apoptosis in OVCAR-3 cells.
Knockdown of p21 by siRNA (50 nM) did not abrogate the
apoptosis and caspase-3/7 enzymatic activation in OVCAR-3
cells which was induced by treatment of myricetin (Fig. 6).
These results indicate that myricetin induced apoptosis in
OVCAR-3 cells through a p21-independent pathway.

Discussion
A pressing problem in cancer treatment is that platinumbased chemotherapy is seriously hampered by high rates
of adverse effects and chemoresistance (21). There exists a
dire need for more selective drugs in the treatment of cancer.
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Previous studies have reported that myricetin induces apoptosis in various cancer cells, such as hepatoma, pancreatic
cancer, esophageal cancer, and colon carcinoma cells
(15-18). However, its effects on ovarian cancer are currently
unknown. In this study, it was found that myricetin was more
cytotoxic to two cisplatin-resistant ovarian cancer cell lines
A2780/CP70 and OVCAR-3 than normal ovarian cells IOSE364, and that myricetin had stronger anticancer activity than
cisplatin in the two ovarian cancer cell lines when compared
to our previous study (19).
The mechanism through which cancer cells develop
resistance to chemotherapy is associated with increased
resistance to apoptosis. In pre-clinical disease models, agents
that induce apoptosis have been reported to sensitize tumor
cells to chemotherapy and radiotherapy (22). There are two
major pathways leading to apoptosis: the intrinsic or mitochondrial and extrinsic or receptor-mediated pathways. The
permeability of the mitochondria and release of cytochrome c
into the cytoplasm will be increased when the intrinsic apoptotic pathway is activated. After that, cytochrome c forms a
multi-protein complex, known as the apoptosome, initiating
activation of caspase-9. Bcl-2 protein family plays an important role in the regulation of the intrinsic apoptotic pathway
through controlling the permeability of the mitochondrial
membrane and the release of pro-apoptotic factors (10).
Whether or not cells will undergo apoptosis is dependent on
the balance between the pro- (such as Bax and Bad) and antiapoptotic (such as Bcl-xl and Bcl-2) proteins of the family
members. In the extrinsic pathway, tumor necrosis factorrelated apoptosis-inducing ligand (TRAIL), including the
Apo2L/TRAIL, regulates the extrinsic apoptotic pathway by
engaging its receptor, such as DR5. The receptor homotypically binds to FAS-associated death domain protein (FADD)
to form death inducing signaling complex (DISC), activating
caspase-8 and -10. Activation of either the intrinsic pathway
of apoptosis or the extrinsic pathway results in activation
of caspase-3 and -7 culminating in apoptosis. In this study,
myricetin was found to induce intrinsic apoptosis through
the Bcl-2 protein but not the caspase-9 enzyme in A2780/
CP70 and OVCAR-3 cells. A previous study indicated that
myricetin induces apoptosis in colon cancer cells through
increasing the ratio of Bax/Bcl-2 proteins (18), which agrees
with the results obtained here. The effect of myricetin on the
extrinsic apoptotic pathway was also examined by testing the
expression of DR5, FADD, and caspase-8 proteins. It was
found that myricetin increased the levels of DR5 protein and
decreased the levels of procaspase-8 in the OVCAR-3 but
not the A2780/CP70 cells, suggesting that myricetin induces
apoptosis in OVCAR-3 cells though a DR5-associated
extrinsic pathway. The alterations in the balance of Bcl-2/
Bax proteins was associated with the differential induction of
apoptosis in cancer versus normal cells (23). Evidence from
clinical trials has indicated that normal cells are resistant to
the tumor necrosis factor-related apoptosis-inducing ligand
(TRAIL), and targeting DR5 selectively eliminates tumor
cells while sparing normal cells (24). This study has shown
that myricetin induced apoptosis in ovarian cancer cells
A2780/CP70 and OVCAR-3 but not normal ovarian cells
IOSE-364, which might be due to its effects on the expression
of the Bcl-2 family and DR5 protein.

The cell cycle represents a series of events that allow
the cell to replicate into two daughter cells. Many cancer
cells have defective G1 checkpoint mechanisms and are
more dependent on the G2 checkpoint during replication
than normal cells. Cancer represents a dysregulation of the
cell cycle, such as an overexpression of cyclins or insufficient expression of CDKIs, which result in cell growth and
tumor formation (7). Therefore, the innovative strategy of
cell cycle arrest, which activates the apoptotic cascade and
leads to cell death, was developed. Novel anticancer drugs
have been focused on as the target of cell cycle control
mechanisms (8,9). Previous studies indicated that myricetin
induces G2/M blockage in human squamous cell carcinoma
cell lines SCC-25 and human colon cancer cell lines HCT116
(25,26). However, in the present study, the cell cycle in
human ovarian cancer cells was not affected by treatment of
myricetin, which means myricetin inhibited ovarian cancer
cell growth through a mechanism separate from inducing
cell cycle arrest.
p53, as a multifunctional tumor suppressor, regulates
cell cycle arrest, transcription, DNA repair, genomic instability, senescence, differentiation, angiogenesis, apoptosis,
and glucose metabolism (20). If the p53 gene is damaged,
tumor suppression will be under serious threat. As shown
in previous studies, p53 alterations, such as loss of function
dominant-negative activity and gain of oncogene function,
has been connected with the failure of chemotherapy and
radiotherapy in a number of cancers (27). More than 50% of
human tumors contain p53 gene that is mutated or deleted
(28), and people who have only one functional copy of the
p53 gene will probably suffer from tumors in early adulthood. Therefore, increasing the amount of p53 might be a
new strategy for treatment of tumors. The intrinsic pathways
of apoptosis such as Bax, Puma, and Noxa are regulated by
p53 (29). It has been reported that the Bcl-2 family genes
are regulated by p53, and cancer cells with loss of p53 function are expected to contain relatively low levels of Bax,
Bad and high levels of Bcl-2 and Bcl-xl (30,31). In ovarian
cancer cells, p53 also has an effect on cell apoptosis (32).
In the present study, myricetin was observed to increase p53
protein expression in the ovarian cancer cells. In OVCAR-3
cells, the myricetin-induced balance alterations of Bcl-2
family proteins were associated with increased p53 protein,
indicating that p53 played an important role in the myricetinactivated intrinsic pathway of apoptosis. The transcription
factor cmyc protein is encoded by a regulator. It is a nuclear
protein which plays a role in the cell cycle, apoptosis, progression, and cellular transformation. Previous studies indicated
that p53-dependent repression of cmyc was involved in cell
cycle arrest and apoptosis (33,34). In this study, myricetin
decreased the cmyc protein expression in A2780/CP70 and
OVCAR-3 cells, and knockdown of protein p53 neutralized
the repressive effect myricetin had on cmyc expression in
OVCAR-3 cells. Therefore, it is reasonable to think that
p53 induced apoptosis through a cmyc-dependent manner.
Of course, more studies are needed to clarify the role of
cmyc in myricetin-induced apoptosis in ovarian cancer cells.
Additionally, it was seen that myricetin increased the expression of p21 protein in both ovarian cancer cell lines, and it
was mediated by p53 in OVCAR-3 cells. Therefore, it was
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inferred that p21 might be involved in myricetin-induced
apoptosis and the inhibition of angiogenesis in OVCAR-3
cells.
P21, known as CDK-interacting protein 1 or cyclindependent kinase inhibitor 1, regulates cell cycle progression,
tightly regulated by p53 protein (35). It has been reported
that myricetin increased levels of p21 protein in HepG2 cells
which resulted in cell cycle arrest at the G2/M phase (36).
However, in the present study, the increased levels of p21
protein had little effect on the cell cycle in A2780/CP70 and
OVCAR-3 cells. Some previous studies indicated that p21 was
a positive regulator of apoptosis in either p53-dependent or
independent pathways, while other studies showed p21 inhibited p53-dependent apoptosis (37). In our study, although
myricetin increased levels of p21 protein in OVCAR-3 cells,
it was not associated with apoptosis.
In conclusion, the present study suggests that myricetin,
which exhibited higher cytotoxicity to two cisplatin-resistant
ovarian cancer cell lines than in normal ovarian cells,
might be a potential candidate for the chemoprevention of
ovarian cancer. It induces apoptosis in both ovarian cancer
cells through a Bcl-2 family protein-associated intrinsic
pathway. In OVCAR-3, myricetin also induces DR-5 associated extrinsic apoptosis. P53 plays an important role in Bcl-2
family protein-dependent apoptosis, induced by myricetin, in
OVCAR-3 cells. Ostensibly, further studies in animal models
and human trials are needed to determine the efficacy of this
compound for the treatment of ovarian cancer.
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